KarXT targets muscarinic receptors in the brain, offering a new treatment for schizophrenia that balances dopamine activity with cognitive and emotional processing effects.
Christoph Correll emphasizes the revolutionary potential of KarXT, stating it may finally provide effective treatment for patients unresponsive to traditional antipsychotics.
The development of KarXT marks a significant advance in schizophrenia treatment, suggesting a future of personalized therapies that better suit individual patient needs.
As more drugs engaging muscarinic receptors enter clinical trials, the therapeutic landscape for schizophrenia may evolve towards greater effectiveness and reduced side effects.
Collection
[
|
...
]